News Ticker

Vaccines Manufacturing and Innovation Centre Fast Tracked as Works Progress at Harwell Campus

Construction of the UK’s New Vaccines Centre by Glencar Construction Starts Well Ahead of Schedule as Timelines are Fast Tracked Due to Covid-19

Construction work has begun ahead of schedule to build the highly specialist facility that will house the Vaccines Manufacturing and Innovation Centre (VMIC). VMIC, a not for profit organisation, will provide the country’s first bespoke strategic vaccine development and manufacturing capability.

A rapidly accelerated programme will aim to see the 7,000 m2 (75,000 sq ft – footprint) state-of-the-art facility opening its doors in 2021, ahead of the original scheduled date in 2022. An unprecedented collaborative effort between The Vaccines Manufacturing and Innovation Centre, Harwell Campus, Vale of the White Horse District Council, UK Research and Innovation, and Glencar Construction, the main contractor, has accelerated the construction of this complex build in order to bring the facility on line early so that it can provide an emergency response capability for the UK.

Ground works began on the site at Harwell Campus in early April and have focused on site clearance, preparing the site for construction and the early order of the steelwork. Glencar expect to see the basebuild ready for early access for fit-out, in late July/early August. Design and fit out are underway and led by WHP Engineering.Dr Matthew Duchars, Chief Executive of the Vaccines Manufacturing and Innovation Centre said:

“Whilst no-one could have predicted the Covid-19 outbreak we are doing all we can to fast track the build so VMIC is set-up to offer long-term support to the UK’s future vaccines needs whilst simultaneously contributing right now to the vital work that will help us emerge from this pandemic.

“As well as working with the Harwell team and contractors to deliver the build rapidly ahead of schedule, VMIC scientists and engineers are working round the clock as part of the BIA CoViD19 Taskforce, and alongside Oxford University advising on manufacturing options of the vaccine candidate ChAdOx1 nCoV-19, which has recently opened for trial.”

Cliff Dare, Chief Operating Officer of Harwell Campus Management team and Development Manager for the VMIC build said:

“This is an unprecedented time and one that calls for collaboration across many fields and sectors. We are working closely with Matthew and his team, national and local government, and Glencar the main contractor involved on this complex development. It is essential that we continue to fast track this project of national importance, bringing the facility into operation as quickly as possible.

“This is not a straightforward build and fit out; it is a complex advanced centre of technology and that throws up its own particular challenges. One way we are addressing this is by looking at novel strategies for developing fit out / technologies, including off-site manufacture that will sit within the building to be developed alongside groundworks.”